Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visugromab plus nivolumab as neoadjuvant therapy for muscle-invasive bladder cancer
2024-513957-55-00Phase 2Completed
- Sponsor
- CatalYm
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC) comparing Visugromab + nivolumab with Nivolumab alone (2 arms). Primary endpoints: Pathological complete response rate and Radiological response rate by RECIST v1.1. Started Jul 2024; status: completed.
02
Drugs
visugromabnivolumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-513957-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513957-55-00.